drugset / Trial / NCT00422955

Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.

NCT00422955

Phase 3 Completed 36 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

Fluid management study in patients with type 2 diabetes and autonomic neuropathy.

Timeline

Start
2003-11
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule 4 mg

Indications